Mazdutide

What it is

Mazdutide (LY3305677, IBI362) is an investigational dual GLP-1/glucagon receptor agonist being developed by Innovent Biologics in collaboration with Eli Lilly. It is in advanced clinical trials, particularly in China where Innovent is based.

Mechanism of action

Dual agonist at GLP-1 and glucagon receptors. The GLP-1 component provides standard incretin effects (insulin secretion, glucagon suppression in glucose-dependent manner, appetite reduction). The glucagon component provides effects on energy expenditure similar to those proposed for retatrutide. The dual mechanism (without GIP) distinguishes it from tirzepatide and retatrutide.

Clinical evidence

Phase III trials in obesity and type 2 diabetes are ongoing, primarily in China. Phase II data showed meaningful weight loss and glycemic improvements. The compound has been considered for regulatory approval in China.

Why we don’t prescribe it at The Tide

Mazdutide is not FDA-approved and not available through legal channels in the US. We do not prescribe medications without appropriate regulatory approval and supply chain.

Side effects and contraindications

Side effect profile similar to other incretin therapies in clinical trials.